Defendant
3 cases as defendant.
Fresenius Kabi AG is a global healthcare company headquartered in Bad Homburg, Germany. The company was formed in 1999 through the merger of Fresenius Group's pharma division with the international nutrition business of Pharmacia & Upjohn (Kabi). It operates as a wholly-owned subsidiary of Fresenius SE & Co. KGaA, a German healthcare group. Fresenius Kabi is a large-scale enterprise, employing over 40,000 people worldwide and reporting sales of more than €8.5 billion in 2025.
Fresenius Kabi specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition for critically and chronically ill patients. The company's product portfolio includes a wide range of I.V. generic drugs, biopharmaceuticals (including biosimilars focused on oncology and autoimmune diseases), and clinical nutrition products. In the medical technology sector, Fresenius Kabi provides infusion pumps, apheresis machines, cell therapy devices, and other medical disposables. The company operates a global network of approximately 60 production sites and has a significant presence in the United States through its subsidiary, Fresenius Kabi USA, LLC, which is based in Lake Zurich, Illinois.
Based on the provided data, Fresenius Kabi is an operating company that acts as a defendant in patent litigation. It has been named as a defendant in three tracked cases and has not appeared as a plaintiff. This defensive posture is typical for a large manufacturer and seller of medical products. All three of the tracked lawsuits were filed in the U.S. District Court for the Northern District of Illinois, where Fresenius Kabi's U.S. subsidiary has an established place of business. This indicates litigation is occurring in a venue connected to the company's U.S. operations rather than a venue chosen solely for its plaintiff-friendly reputation.
The three tracked cases, all filed on the same day, are part of litigation brought by Haemonetics Corporation. The lawsuits allege that Fresenius Kabi's Aurora Xi Plasmapheresis System infringes on three of Haemonetics' patents. The patents in question relate to systems and methods for optimizing the collection of plasma from donors by more accurately calculating the volume of pure plasma collected. This legal challenge targets a specific product line within Fresenius Kabi's transfusion technology and cell therapies business.
The complaint alleges that the defendants' Aurora Xi Plasmapheresis System infringes U.S. Patent No. 12,186,474, among other patents related to systems and methods for optimizing plasma collection.
Haemonetics alleges that the Aurora Xi Plasmapheresis System infringes upon three of its patents, including US patent 12,171,916. The case is currently active.
Haemonetics alleges that the defendants' Aurora Xi Plasmapheresis System infringes on its patents related to optimized plasma collection. The case is described as being connected to litigation involving the '416 patent family.